DUBLIN--(BUSINESS WIRE)--Oct 21, 2019--

The "Vascular Ehlers-Danlos Syndrome - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

A detailed picture of the Vascular Ehlers-Danlos Syndrome pipeline landscape is provided which includes the disease overview and Vascular Ehlers-Danlos Syndrome treatment guidelines.

The assessment part of the report embraces in depth Vascular Ehlers-Danlos Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vascular Ehlers-Danlos Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Vascular Ehlers-Danlos Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Vascular Ehlers-Danlos Syndrome targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Vascular Ehlers-Danlos Syndrome pipeline report covers 2+ companies. Some of the key players include Acer Therapeutics (Celiprolol) etc.

Vascular Ehlers-Danlos Syndrome Analytical Perspective

In-depth Vascular Ehlers-Danlos Syndrome Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs and have included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Vascular Ehlers-Danlos Syndrome Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

  • The Vascular Ehlers-Danlos Syndrome report provides an overview of therapeutic pipeline activity for Vascular Ehlers-Danlos Syndrome across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Vascular Ehlers-Danlos Syndrome therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Vascular Ehlers-Danlos Syndrome Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Vascular Ehlers-Danlos Syndrome

Key Topics Covered:

1. Report Introduction

2. Vascular Ehlers-Danlos Syndrome (Ehlers-Danlos type IV)

2.1. Vascular Ehlers-Danlos Syndrome Disease Overview

2.2. Vascular Ehlers-Danlos Syndrome History

2.3. Vascular Ehlers-Danlos Syndrome Symptoms

2.4. Vascular Ehlers-Danlos Syndrome Causes

2.5. Vascular Ehlers-Danlos Syndrome Pathophysiology

2.6. Vascular Ehlers-Danlos Syndrome Diagnosis

2.6.1. Diagnostic Guidelines

3. Vascular Ehlers-Danlos Syndrome Current Treatment Patterns

3.1. Treatment Guidelines

4. Vascular Ehlers-Danlos Syndrome- An Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Vascular Ehlers-Danlos Syndrome companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Vascular Ehlers-Danlos Syndrome Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Vascular Ehlers-Danlos Syndrome Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.3. Assessment by Route of Administration

4.2.4. Assessment by Molecule Type

4.2.5. Assessment by MOA

5. Vascular Ehlers-Danlos Syndrome Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.2. Mid Stage Products (Phase-II)

5.3. Early Stage Products (Phase-I)

5.4. Pre-clinical and Discovery Stage Products

5.5. Inactive Products

6. Vascular Ehlers-Danlos Syndrome-Products Analysis

6.1. Product Profiles

6.1.1. Celiprolol- Acer Therapeutics

6.1.1.1. Product Description

6.1.1.1.1. Product Overview

6.1.1.1.2. Mechanism of Action

6.1.1.2. Research and Development

6.1.1.2.1. Clinical Studies

6.1.1.2.1.1. Detailed Study Description

6.1.1.2.1.2. Study Results

6.1.1.2.1.3. Clinical Trials: Tabular View

6.1.1.3. Product Development Activities

6.1.1.3.1. Tabulated Product Summary

6.1.1.3.1.1. General Description Table

7. Recent Technologies

8. Vascular Ehlers-Danlos Syndrome Key Companies

8.1. Acer Therapeutics

8.2. Fibrocell Science

9. Vascular Ehlers-Danlos Syndrome Key Products

9.1. Celiprolol

9.2. Research programme: fibroblast autologous cell therapies

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Vascular Ehlers-Danlos Syndrome- Unmet Needs

12. Vascular Ehlers-Danlos Syndrome- Future Perspectives

13. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nlgz55

View source version on businesswire.com:https://www.businesswire.com/news/home/20191021005428/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL MANAGED CARE

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 10/21/2019 09:52 AM/DISC: 10/21/2019 09:52 AM

http://www.businesswire.com/news/home/20191021005428/en

Copyright Business Wire 2019.

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Thank you for Reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.